Keytruda Plus T-VEC Falls Short in Unresectable Melanoma

(MedPage Today) -- Pembrolizumab (Keytruda) plus intratumoral talimogene laherparepvec (T-VEC, Imlygic) did not significantly improve survival in unresectable melanoma as compared with pembrolizumab alone, an international phase III trial showed...